1887

Chapter 10 : Immune Complex Reactions

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Immune Complex Reactions, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818012/9781555812027_Chap10-1.gif /docserver/preview/fulltext/10.1128/9781555818012/9781555812027_Chap10-2.gif

Abstract:

Immune complex reactions are caused by immunoglobulin antibody reacting directly with tissue antigens (usually basement membrane antigens) or by antibody reacting with soluble antigen in the blood to form soluble antigen-antibody complexes that deposit in tissues. The Arthus reaction is a dermal inflammatory response caused by the reaction of precipitating antibody with antigen placed in the skin. The lesions of serum sickness directly correlate with the presence of soluble immune complexes. Human and experimental glomerulonephritis may also be initiated by antibodies to glomerular basement membrane (anti-GBM) or to antigens on epithelial cells. The experimental model is known as experimental autoimmune glomerulonephritis; the human diseases caused by anti-GBM are poststreptococcal glomerulonephritis, Goodpasture's disease, and anti-GBM nephritis associated with vasculitis. The major pathologic features of rheumatic fever are widespread inflammation and scarring in connective tissue in the heart, joints, lungs, pleura, subcutaneous tissue, and skin. The diffuse connective tissue diseases include rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, polymyositis (dermatomyositis), and progressive systemic sclerosis (scleroderma). The major pathologic changes of systemic lupus erythematosus (SLE) most frequently involve the kidney and skin, but systemic vasculitis may lead to symptoms relating to any organ of the body. In addition to the renal glomerulus, other organs of the body also contain capillary basement membrane exposed to circulating blood: the lung, synovial capillaries, the choroid plexus of the brain, and the uveal tract of the eye. These organs are susceptible to anti-basement membrane antibody attack and deposition of immune complexes.

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 10.1
Figure 10.1

Immune complex reactions. Antibody (usually IgG) reacts with soluble antigens to produce soluble circulating immune complexes or with basement membranes (such as renal glomerular basement membrane). Antibody-antigen complexes cause activation of complement with formation of inflammatory (phlogistic) complement fragments. Fragments C3a, C4a, and C5a (anaphylatoxin) cause constriction of vascular endothelium (increased vascular permeability). C5a is also chemotactic for polymorphonuclear leukocytes, and C3b enhances phagocytosis. Released lysosomal polymorphonuclear enzymes digest tissues, producing “fibrinoid” necrosis. Fibrinoid means “fibrinlike” and refers to the histologic appearance of the acellular amorphous areas produced by “digestion” of tissue by lysosomal enzymes that resemble the appearance of fibrin in clotted blood.

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 10.2
Figure 10.2

Comparison of double diffusion in agar precipitin reaction and Arthus reaction. When antibody and antigen are allowed to diffuse toward each other in agar, a precipitin band forms when the antigen and antibody concentration in the agar are in equivalence. Similarly, if antigen is injected into the skin, it will diffuse toward the vessels. The major precipitin reaction occurs in the walls of small vessels, usually arterioles, where antibody in the circulation diffuses out to meet antigen diffusing in from the tissue.

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 10.3
Figure 10.3

Steps in the Arthus reaction. (1) Injection of antigen into the dermis. (2) Diffusion of antigen in tissue to vessels. (3) Reaction of antigen with circulating antibody in the wall of small arterioles. (4) Formation of antibody-antigen complexes, aggregation of Fc of antibody, and activation of complement. (5) Contraction and separation of endothelial cells by C3a, C5a (anaphylatoxin), and attraction of neutrophils by C5a and C5a des-Arg chemotactic factors. (6) Activation of neutrophils in vessel wall with release of lysosomal enzymes. (7) Digestion of vascular wall producing fibrinoid necrosis. (8) Resolution or scarring, depending on severity of reaction.

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 10.4
Figure 10.4

Steps in serum sickness. (1) Formation of soluble antibody-antigen complexes in circulation. Such complexes do not fix complement because Fcs are not aggregated. (2) Soluble complexes pass through open endothelial spaces in glomeruli and deposit on the epithelial side of the basement membrane or in walls of small arteries. Accumulation of complexes results in formation of aggregates of immunoglobulin, activating complement. (3) Neutrophils are attracted, pass into basement membrane or vessel wall, and release lysosomal enzymes, causing destruction of basement membranes.

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 10.5
Figure 10.5

Comparison of antigen elimination, precipitin reaction, and serum complement levels during experimental serum sickness. Immune elimination of antigen follows production of antibody that binds to antigen in the circulation. When antibody first appears, there is an excess of antigen so that soluble immune complexes in antigen excess are formed. These complexes lodge in arteries and, in particular, in glomeruli, where aggregates of immunoglobulin fix complement. This results in lesions of serum sickness and a fall in serum complement. As more antibody is produced, complexes in equivalence and then antibody excess are found. Since these complexes contain aggregated Fc regions of immunoglobulin, they will be cleared from the circulation by the reticuloendothelial system because of receptors on macrophages for aggregated Fc and C3b.

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 10.6
Figure 10.6

Pathogenesis of glomerulonephritis. Depicted is part of a glomerulus. The mesangial cells are located in the center and support the endothelial cells (END), which line the inside of the basement membrane. There are gaps in the cytoplasm of the endothelial cells, which expose the basement membrane to blood components. The upper left part of the figure illustrates deposition of antiglomerular basement membrane (anti-GBM) antibody as a linear deposit of immunoglobulin on the endothelial side of the basement membrane. The upper right depicts deposition of soluble immune complexes on exposed basement membrane after contraction of endothelial cells by vasoactive amines or activation of anaphylatoxin. The lower left segment illustrates that the complexes may deposit as large clumps, distorting the foot processes of the endothelial cells. Dissolution of the basement membrane by release of lysosomal enzymes from polymorphonuclear leukocytes (POLYS) activated by complement or alterations in the electrostatic properties of the basement membrane by anti-GBM or immune complex deposition leads to leakage of proteins into the urine (proteinuria) (upper right). If more extensive destruction of the basement membranes occurs, cellular elements of the blood, as well as basement membrane fragments, may be detected in the urine. Prolonged accumulation of immune reactants leads to thickening of the basement membrane and fusion of the foot processes of epithelial cells (EPI). Clinically, this is expressed as a loss of the filtering capacity of the kidney and retention of toxic metabolites (uremia).

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 10.7
Figure 10.7

Effect of charge on immune complex localization in glomeruli. Cationic immune complexes (positively charged) preferentially localize in the glomerular basement membrane (A). Subepithelial localization may be explained by a higher density of anions on the epithelial side of the basement membrane. Cationic free antigen may deposit in the basement membrane (B), and subsequent reaction with antibody leads to formation of immune complexes within the basement membrane. Anionic complexes tend to be taken up by the mesangial cells (C) and are less pathogenic but may also localize on the endothelial side of the basement membrane (D).

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 10.8
Figure 10.8

Schematic localization of Goodpasture antigen α3 chain of type IV collagen in glomerular basement membrane. The endothelial and epithelial surface of the glomerular basement membrane is lined with laminin, the membrane itself is composed of a scaffold of two subtypes of type IV collagen molecules (building blocks). Subtype A (classical) contains α1 and α2 chains; subtype B contains the α3 chain (Goodpasture antigen). The endothelial surface has a net negative charge; it repels negatively charged antibodies, but cationic antibodies pass into the membrane to react with Goodpasture antigen. Serum of patients with poststreptococcal glomerulonephritis may bind with any of the major components of the basement membrane. (Modified from B. G. Hudson, J. Wieslander, B. J. Wisdom, Jr., and M. E. Noelken, Lab. Investig. 61:256–269, 1989.)

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 10.9
Figure 10.9

Glomerulonephritis: clinical-pathologic correlations. The mechanisms of glomerulonephritis illustrated may produce a varied clinical and pathologic picture. (I) Anti-glomerular basement membrane antibody reacts with antigens on the lumenal side of the glomerular basement membrane and produces a linear deposition when examined by immunofluorescence. (II) Soluble immune complexes formed elsewhere pass through the glomerular basement membrane and lodge on the epithelial side, producing lumpy-bumpy deposits, or lodge within or on the endothelial side of the basement membrane as granular deposits. Granular deposit disease may also be produced from endothelial cell surface antigen- antibody complexes shed into the basement membrane. (III) Complement in the absence of immunoglobulin may be detected as a granular deposit. Hypocomplementemic glomerulonephritis may be caused by a preceding immunoglobulin deposit or by the action of properdin, both of which may activate complement. No single mechanism produces a particular type of clinical picture or pathologic lesion, although hypocomplementemic glomerulonephritis is usually of the chronic variety. A capillary lumen, basement membrane endothelial cell foot plates, and an epithelial cell are illustrated. (Modified from an illustration by C. Wilson, Scripps Clinic and Research Foundation, La Jolla, Calif.)

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 10.10
Figure 10.10

The immune response to streptococcal group A antigens and rheumatic fever. Antibodies produced to streptococcal antigens cross-react with host tissue antigens. These “autoantibodies,” as well as soluble immune complexes, are responsible for the lesions of rheumatic fever (myocarditis, endocarditis, arthritis, vasculitis, and glomerulonephritis).

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 10.11
Figure 10.11

Pathologic features of connective tissue diseases. The relative frequency of the lesions associated with connective tissue diseases (bottom) is indicated by the thickness of the boxes (top). Serum sickness is included because its characteristic lesions (vasculitis, glomerulonephritis, myocarditis, and arthritis) are also found in the connective tissue diseases. This suggests a primary role for immune complex mechanisms in connective tissue disease.

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 10.12
Figure 10.12

Current concepts of the pathogenesis of rheumatoid arthritis postulate that an as yet unidentified antigen (infectious agent, host autoantigen) present in the joint cavity stimulates the production of an antibody. Antigen-antibody complexes that produce an alteration in the tertiary structure of the antibody, revealing new or buried antigenic determinants, are formed. These determinants in turn stimulate the production of another antibody, RF (IgM or IgG), which can react with IgG. Complexes form in the synovial fluid and activate complement components which attract PMNs. A proliferation of lymphocytes and plasma cells in the synovial lining tissue converts the synovium into a lymphoid organ, which produces RF that is released locally into the synovial fluid. TDTH lymphocytes in the synovium are activated to produce lymphokines that attract and activate macrophages. Activated macrophages and lymphocytes secrete cytokines that upregulate expression of cell adhesion molecules on endothelial cells and synovial fibroblasts. Macrophages also produce osteoclast activating factor and other activation factors that lead to destruction of adjacent bone. Hyperplasia of granulation tissue and inflammatory cells occurs and extends as a mass (pannus) over the articular cartilage. The pannus produces collagenase and elastase that destroys the joint cartilage. This pannus may progress to form a scar in the joint that leads to immobilization.

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 10.13
Figure 10.13

Formation of LE cells. LE cells are PMNs that have phagocytosed the nuclei of lymphocytes by coating the nuclei with antibody. This takes place at 37°C upon incubation of the whole blood of a patient with SLE who has antibody to nucleoprotein or other nuclear antigens. Lymphocytes break up, and lymphocyte nuclei become coated with antibody (LE factor), swell, and are phagocytosed by PMNs. LE cells may also be formed by phagocytosis of the nuclei of cells other than lymphocytes.

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555818012.chap10
1. Cochrane, C. G.,, and D. Koffler. 1973. Immune complex disease in experimental animals and in man. Adv. Immunol. 16:185264.
2. Heller, T.,, J. E. Gessner,, R. E. Schmidt,, A. Klos,, W. Bautsch,, and J. Kohl. 1999. Cutting edge: Fc receptor type I for IgG on macrophages and complement mediate the inflammatory response in immune complex peritonitis. J. Immunol. 162: 56575661.
3. Oldham, K. T.,, K. S. Guice,, P. A. Ward,, and K. J. Johnson. 1988. The role of oxygen radicals in immune complex injury. Free Radical Biol. Med. 4:387397.
4. Arthus, M. 1903. Injections répétées de sérum de cheval chez le lapin. C. R. Soc. Biol. (Paris) 55:817.
5. Steil, A. A.,, C. F. Teixeira,, and S. Jancar. 1999. Platelet-activating factor and eicosanoids are mediators of local and systemic changes induced by immune-complexes in mice. Prostaglandins Other Lipid Mediat. 57:3548.
6. Bielory, L.,, P. Gascon,, T. J. Lawley,, N. S. Young,, and M. Frank. 1988. Human serum sickness: a prospective analysis of 35 patients treated with equine antithymocyte globulin for bone marrow failure. Medicine 67:4057.
7. Dixon, F. J.,, J. J. Vasquez,, W. O. Weigle,, and C. G. Cochrane. 1958. Pathogenesis of serum sickness. Arch. Pathol. 65:1828.
8. Gaig, P.,, P. Garcia-Ortega,, E. Enrique,, A. Benet,, B. Bartolome,, and R. Palacios. 1999. Serum sickness-like syndrome due to mosquito bite. J. Investig. Allergol. Clin. Immunol. 9:190192.
9. von Pirquet, C. F.,, and B. Schick. 1951. Serum Sickness (B. Schick, trans.). The Williams & Wilkins Co., Baltimore, Md. [Reprint of 1905 article.]
10. Vozianova, Z. I.,, and K. I. Chepilko. 1999. Serum sickness in diphtheria. Lik. Sprava. 3:126128.
11. Winter, G.,, and W. J. Harris. 1993. Humanized antibodies. Trends Pharmacol. Sci. 14:139143.
12. Andres, G.,, J. R. Brentjens,, P. R. B. Caldwell,, G. Camussi,, and S. Matsuo. 1986. Biology of disease. Formation of immune deposits and disease. Lab. Investig. 55:510520.
13. Bruijn, J. A.,, P. J. Hoedemaeker,, and G. J. Fleuren. 1989. Pathogenesis of anti-basement membrane glomerulonephritis and immune-complex glomerulonephritis: dichotomy dissolved. Lab. Investig. 61:480488.
14. Feintzeig, I. D.,, J. E. Dittmer,, A. V. Cybulsky,, and D. J. Salant. 1986. Antibody, antigen and glomerular capillary wall charge interactions: influence of antigen location on in situ immune complex formation. Kidney Int. 29:649657.
15. Foster, M. H.,, and V. R. Kelly. 1999. Lupus nephritis: update on pathogenesis and disease mechanisms. Semin. Nephrol. 19:173181.
16. Hudson, B. G.,, J. Wieslander,, B. J. Wisdom,, and M. E. Noelken. 1989. Goodpasture syndrome: molecular architecture and function of basement membrane antigen. Lab. Investig. 61:256269.
17. Julian, B. A.,, M. Tomana,, J. Novak,, and J. Mestecky. 1999. Progress in the pathogenesis of IgA nephropathy. Adv. Nephrol. Necker Hosp. 29:5372.
18. Kitching, A. R.,, S. R. Holdsworth,, and P. G. Tipping. 1999. INF-gamma mediates crescent formation and cell-mediated immune injury in murine glomerulonephritis. J. Am. Soc. Nephrol. 10:752759.
19. Krane, N. K.,, and P. Gaglio. 1999. Viral hepatitis as a cause of renal disease. South. Med. J. 92:354360.
20. Muda, A. O.,, S. Feriozzi,, S. Rahimi,, E. Ancarani,, and T. Faraggiana. 1999. Spatial arrangement of subepithelial deposits in lupus and nonlupus membranous nephropathy. Am. J. Kidney Dis. 34:8591.
21. Rychlik, I.,, K. Andrassy,, R. Waldherr,, I. Zuna,, V. Tesar,, E. Jancova,, A. Stejskalova,, and E. Ritz. 1999. Clinical features and natural history of IgA nephropathy. Ann. Med. Interne (Paris) 150:117126.
22. Ryffel, B.,, H. Eugster,, C. Haas,, and M. Le Hir. 1998. Failure to induce antiglomerular basement membrane glomerulonephritis in TNF α/β deficient mice. Int. J. Exp. Pathol. 79:453460.
23. Schneider, A.,, U. Panzer,, G. Zahner,, U. Wenzel,, G. Wolf, et al. 1999. Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-beta. Kidney Int. 56:135144.
24. Behçet, H. 1937. Über rez’diverende Aphtose durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalen. Dermatol. Wochenschr. 105:1152.
25. Clark, J. A. 1995. Unraveling the mystery: clues to systemic vasculitic disorders. AACN Clin. Issues 6:645656.
26. Csernok, E.,, A. Muller,, and W. L. Gross. 1999. Immunopathology of ANCA-associated vasculitis. Intern. Med. 38:759765.
27. Curtis, N.,, and M. Levin. 1998. Kawasaki disease thirty years on. Curr. Opin. Pediatr. 10:2433.
28. Ghate, J. F.,, and J. L. Jorizzo. 1999. Behçet’s disease and complex aphthosis. J. Am. Acad. Dermatol. 40:118.
29. Hunder, C. G.,, J. T. Lie,, J. J. Goronzy,, and C. M. Weyand. 1993. Pathogenesis of giant cell arteritis. Arth. Rheum. 36:757761.
30. Laupland, K. B.,, and H. Dele Davies. 1999. Epidemiology, etiology, and management of Kawasaki disease: state of the art. Pediatr. Cardiol. 20:177183.
31. LeRoy, E. C. (ed.). 1992. Systemic Vasculitis: the Biologic Basis. Marcel Dekker, Inc., New York, N.Y..
32. Mochizuki, M. 1997. Immunotherapy for Behçet’s disease. Int. Rev. Immunol. 14:4966.
33. Piette, J. C. C. Fieschi, and Z. Amoura. 1999. Classification of vasculitis. N. Engl. J. Med. 341:11741175.
34. Brandt, E. R.,, and M. F. Good. 1999. Vaccine strategies to prevent rheumatic fever. Immunol. Res. 19:89103.
35. Froude, J.,, A. Gibofsky,, D. R. Buskirk,, A. Khanna,, and J. B. Zabriskie. 1989. Cross-reactivity between streptococcus and human tissue: a model of molecular mimicry and autoimmunity. Curr. Top. Microbiol. Immunol. 145:526.
36. Groves, A. M. 1999. Rheumatic fever and rheumatic heart disease: an overview. Trop. Doct. 29:129132.
37. McCarty, M.,, and W. Lewis. 1985. Waunamaker in the campaign against rheumatic fever. Zentbl. Bakteriol. Hyg. A 260:151164.
38. Stollerman, G. H. 1991. Rheumatogenic streptococci and autoimmunity. Clin. Immunol. Immunopathol. 61:131142.
39. Benedek, T. G. 1987. A century of American rheumatology. Ann. Intern. Med. 106:304312.
40. Farid, N. R. 1990. The Immunogenetics of Autoimmune Diseases. CRC Press, Boca Raton, Fla..
41. Klemperer, P. 1961. The concept of collagen diseases in medicine. Am. Rev. Respir. Dis. 83:331339.
42. Guillevin, L. 1999. Treatment of classic polyarteritis nodosa in 1999. Nephrol. Dial. Transplant. 14:20772079.
43. Kussmaul, A.,, and R. Maier. 1866. Ueber eine bisher nicht beschriebene eigenthumliche Arterienerkrankung (Periarteritis Nodosa), die mit Morbus Brightii and rapid fortschreitender allgemeiner Muskellahmung einhergeht. Dtsch. Arch. Klin. Med. 1:484.
44. McCombs, R. P. 1965. Systemic “allergic” vasculitis: clinical and pathological relationships. JAMA 194:10591064.
45. Phanuphak, P.,, and P. F. Kohler. 1980. Onset of polyarteritis nodosa during allergic hypersensitization treatment. Am. J. Med. 68:479485.
46. Soufir, N.,, V. Descamps,, B. Crickx,, V. Thibault,, A. Cosnes,, P. A. Becherel, et al. 1999. Hepatitis C virus infection in cutaneous polyarteritis nodosa: a retrospective study of 16 cases. Arch. Dermatol. 135:10011002.
47. Trepo, C. G.,, J. Thivolet,, and A. M. Prince. 1972. Australia antigen and polyarteritis nodosa. Am. J. Dis. Child. 123:390392.
48. Arnett, F. C., 1986. Immunogenetics and arthritis, p. 405. In D. J. McCarty (ed.), Arthritis and Allied Conditions. Lea & Febiger, Philadelphia, Pa..
49. Felson, D. T.,, J. J. Anderson,, M. Boers,, C. Bombardier,, M. Chernoff, et al. 1993. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arth. Rheum. 36:729740.
50. Lipsky, P. E.,, L. S. Davis,, J. J. Cush,, and N. Oppenheimer-Marks. 1989. The role of cytokines in the pathogenesis of rheumatoid arthritis. Springer Semin. Immunopathol. 11:123162.
51. Lockwood, C. M.,, J. D. Elliott,, L. Brettman,, G. Hale,, P. Rebello, et al. 1999. Anti-adhesion molecular therapy as an interventional strategy for autoimmune inflammation. Clin. Immunol. 93:93106.
52. Mellbye, O. J.,, O. Forre,, T. E. Mollnes,, and L. Kvarnes. 1991. Immunopathology of subcutaneous rheumatoid nodules. Ann. Rheum. Dis. 50:909912.
53. Moore, T. L.,, and R. W. Dorner. 1993. Rheumatoid factors. Clin. Biochem. 26:7584.
54. Pincus, T.,, J. R. O’Dell,, and J. M. Kremer. 1999. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann. Intern. Med. 131:768774.
55. Shimoyama, Y.,, J. Nagafuchi,, N. Suzuki,, T. Ochi,, and T. Sakane. 1999. Synovial infiltrating T cells induce excessive synovial cell function through CD28/B7 pathway in patients with rheumatoid arthritis. J. Rheumatol. 26:20942101.
56. Vaughn, J. H. 1993. Pathogenic concepts and origins of rheumatoid factor in rheumatoid arthritis. Arth. Rheum. 36:16.
57. Zvailfer, N. J. 1974. Rheumatoid synovitis. An extravascular immune complex disease. Arth. Rheum. 17:297305.
58. Gonzalez, S.,, J. Martinez-Borra,, and C. Lopez-Larrea. 1999. Immunogenetics, HLA-B27 and spondyloarthropathies. Curr. Opin. Rheumatol. 11:257264.
59. Marker-Hermann, E.,, and T. Hohler. 1999. Pathogenesis of human leukocyte B27- positive arthritis. Information from clinical materials. Rheum. Dis. Clin. N. Am. 24:865881.
60. Ringose, J. H. 1999. HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27? Ann. Rheum. Dis. 58:598610.
61. Scofield, R. H.,, W. L. Warren,, G. Koelsch,, and J. B. Harley. 1973. A hypothesis for the HLA-B27 immune dysregulation in spondyloarthropathy: contributions from enteric organisms, B27 structure, peptides bound by B27, and convergent evolution. Proc. Natl. Acad. Sci. USA 90:93309334.
62. Taurog, J. D.,, S. D. Maika,, N. Satumtira,, M. L. Dorris,, I. L. McLean,, H. Yanagisawa, et al. 1999. Inflammatory disease in HLA-B27 transgenic rats. Immunol. Rev. 169:209223.
63. Arnett, F. C. 1985. HLA and genetic predisposition to lupus erythematosus and other dermatologic disorders. J. Am. Acad. Dermatol. 13:472481.
64. Blatt, N. B.,, and G. D. Glick. 1999. Anti-DNA autoantibodies and systemic lupus erythematosus. Pharmacol. Ther. 83:125139.
65. Brooks, E. B.,, and M. H. Liang. 1999. Evaluation of recent clinical trials in lupus. Curr. Opin. Rheumatol. 11:341347.
66. Foster, M. H.,, and V. R. Kelley. 1999. Lupus nephritis: update on pathogenesis and disease mechanisms. Semin. Nephrol. 19:173181.
67. Hargraves, M. M.,, H. Richmond,, and R. Morton. 1948. Presentation of 2 bone marrow elements: the “tart” cell and the “LE” cell. Mayo Clin. Proc. 23:2531.
68. Rubin, R. L. 1999. Etiology and mechanisms of drug-induced lupus. Curr. Opin. Rheumatol. 11:357363.
69. Southeimer, R. D. 1996. Photoimmunology of lupus erythematosus and dermatomyositis: a speculative review. Photochem. Photobiol. 63:583594.
70. Steinberg, A. D. 1992. Concepts of pathogenesis of systemic lupus erythematosus. Clin. Immunol. Immunopathol. 63:1922.
71. Sullivan, K. E. 1998. Complement deficiency and autoimmunity. Curr. Opin. Pediatr. 10:600606.
72. Tan, E. M.,, A. S. Cohen,, J. F. Fries,, A. T. Masi,, D. J. McShane, et al. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arth. Rheum. 25:12711277.
73. Bell, M.,, A. Askari,, A. Bookman,, S. Frydrych,, J. Lamont,, J. McComb,, C. Muscoplat,, and A. Slomovic. 1999. Sjögren’s syndrome: a critical review of clinical management. J. Rheumatol. 26:20512061.
74. Fox, R. I.,, J. Tronwell,, and P. Michelson. 1999. Current issues in the diagnosis and treatment of Sjögren’s syndrome. Curr. Opin. Rheumatol. 11:364371.
75. Hadden, W. B. 1888. On “dry mouth,” or suppression of the salivary buccal secretions. Trans. Clin. Soc. Hand 21:176.
76. Humphreys-Beher, M. G.,, and A. B. Peck. 1999. New concepts for the development of autoimmune endocrinopathy derived from studies with the NOD mouse model. Arch. Oral Biol. 44(Suppl. 1:S21S25.
77. Mikulicz, J. 1937. Concerning a peculiar symmetrical disease of the lacrimal and salivary glands, p. 137186. In Medical Classics, vol. 2. The Williams & Wilkins Co., Baltimore, Md. [Reprint of 1892 article.]
78. Sjögren, H. 1933. Zur Kenntnis der keratoconjunctivitis sicca (keratitis filiformus bei Hypofunktion der Tränendrüsen). Acta Ophthalmol. (Copenhagen) 11:1.
79. Voulgarelis, M.,, U. G. Dafni,, D. A. Isenberg,, and H. M. Moutsopoulos. 1999. Malignant lymphoma in primary Sjögren’s syndrome: a multicenter, retrospective, clinical study by the European Concentrated Action on Sjögren’s syndrome. Arth. Rheum. 42:17651772.
80. Xanthou, G.,, N. I. Tapinos,, M. Polihronis,, I. P. Nezis,, L. H. Margaritis,, and H. M. Moutsopoulos. 1999. CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjögren’s syndrome. Clin. Exp. Immunol. 118:154163.
81. Dalakas, M. C. 1998. Molecular immunology and genetics of inflammatory muscle diseases. Arch. Neurol. 55:15091512.
82. Dalakas, M. C. 1999. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22:14791497.
83. Vogel, H. 1998. Inclusion body myositis—a review. Adv. Anat. Pathol. 5:164169.
84. Wagner, E. 1886. Ein Fall von akuter Polymyositis. Dtsch. Arch. Klin. Med. 11:241.
85. West, J. E.,, and A. M. Reed. 1999. Analysis of HLA-DM polymorphism in juvenile dermatomyositis (JDM) patients. Hum. Immunol. 60:255258.
86. Brautbar, N.,, A. Vojdani,, and A. W. Campbell. 1992. Silicone implants and systemic immunological disease: review of the literature and preliminary results. Toxicol. Ind. Health 8:231237.
87. Claman, H. N.,, B. D. Jafee,, J. C. Huff,, and R. A. F. Clark. 1985. Chronic graft vs. host disease as a model for scleroderma. Cell. Immunol. 94:7384.
88. Kaal, S. E.,, F. H. Ven Den Hoogen,, E. M. de Jong,, and H. E. Vietor. 1999. Systemic sclerosis: new insights in autoimmunity. Proc. Soc. Exp. Biol. Med. 222:18.
89. Kerin, K.,, and J. H. Yost. 1998. Advances in the diagnosis and management of scleroderma-related vascular complications. Comp. Ther. 24:574581.
90. LeRoy, E. C.,, C. Black,, R. Fleischmajer,, S. Jablonska, et al. 1988. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15: 202205.
91. Lock, G.,, A. Holstege,, B. Lang,, and J. Scholmerich. 1977. Gastrointestinal manifestations of progressive systemic sclerosis. Am. J. Gastroenterol. 92:763771.
92. Nelson, J. L. 1998. Microchimerism and the pathogenesis of systemic sclerosis. Curr. Opin. Rheumatol. 10:564571.
93. Alarcon-Segovia, D. 1981. Mixed connective tissue disease—a decade of growing pains. J. Rheumatol. 8:535540.
94. Brandt, M. A.,, R. W. Hoffman,, S. L. Deutscher,, G. S. Wang,, J. C. Johnson,, and G. C. Sharp. 1999. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arth. Rheum. 42:899909.
95. Kasukawa, R. 1999. Mixed connective tissue disease. Intern. Med. 38:386393.
96. Brain, M. C.,, and P. B. Neame. 1983. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Semin. Thromb. Hemost. 8:186197.
97. Moake, J. L. 1999. Thrombotic thrombocytopenic purpura today. Hosp. Pract. 34:5359.
98. Brentjens, J. R.,, D. W. O’Connel,, I. B. Pawlowski,, K. C. Hsu,, and C. A. Andres. 1974. Experimental immune complex disease of the lung: the pathogenesis of a laboratory model resembling certain interstitial lung diseases. J. Exp. Med. 140:105125.
99. Maumenee, A. E.,, and A. M. Silverstein (ed.). 1964. Immunopathology of Uveitis. The Williams & Wilkins, Co., Baltimore, Md..
100. Murray, P. I.,, C. D. Clay,, C. Mappin,, and M. Salmon. 1999. Molecular analysis of resolving immune responses in uveitis. Clin. Exp. Immunol. 117:455461.
101. Smith, J. R.,, P. H. Hart,, and K. A. Williams. 1998. Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol. Cell. Biol. 76:497512.

Tables

Generic image for table
Table 10.1

Classification of immune complex glomerular disease

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Generic image for table
Table 10.2

Some forms of glomerulonephritis of humans a

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Generic image for table
Table 10.3

Pathologic overlap in selected vasculitis syndromes a

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Generic image for table
Table 10.4

Revised criteria for the diagnosis of rheumatic fever (updated 1992) a

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Generic image for table
Table 10.5

The 1987 revised criteria for the classification of rheumatoid arthritis (traditional format) a

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Generic image for table
Table 10.6

Spondyloarthropathies associated with HLA-B27 a

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Generic image for table
Table 10.7

The 1982 revised criteria for classification of systemic lupus erythematosus a

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Generic image for table
Table 10.8

Some reactivities of antinuclear antibodies a

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Generic image for table
Table 10.9

Nuclear staining patterns observed in patients with connective tissue diseases

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Generic image for table
Table 10.10

Autoantibodies in SLE and other connective tissue diseases a

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Generic image for table
Table 10.11

Genetic features of SLE

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Generic image for table
Table 10.12

Characteristics of inflammatory myopathies a

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10
Generic image for table
Table 10.13

Symptoms and lesions of PSS

Citation: Sell S. 2001. Immune Complex Reactions, p 302-358. In Immunology, Immunopathology, and Immunity, Sixth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818012.ch10

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error